

THE SCIENTIFIC DISCOURSE ON PHARMACOLOGY AND BIOINFORMATIC
ANALYSIS IN MODERN DRUG DESIGN: FROM TARGET DISCOVERY TO
TRANSLATIONAL OPTIMIZATION THROUGH INTEGRATED MOLECULAR,
COMPUTATIONAL, STRUCTURAL, SYSTEMS AND PRECISION MEDICINE
APPROACHES

DOI: <https://doi.org/10.52340/spectri.2026.13.01.06>

^{1,2,3,4,5,6}Nodar Sulashvili, MD, PhD, Professor; Tbilisi, Georgia. <https://orcid.org/0000-0002-9005-8577>

⁷Margarita Beglaryan ², MD, PhD, Academician, Professor; Yerevan, Armenia;
<https://orcid.org/0000-0003-3697-6390>

⁶Nana Gorgaslidze, MD, PhD Professor; Tbilisi, Georgia. <https://orcid.org/0000-0002-4563-5224>

⁷Naira Chichoyan, MD, PhD, Professor; Yerevan, Armenia. <https://orcid.org/0000-0003-3905-3372>

⁸Vira Kravchenko, MD, PhD, Academician, Professor; Kharkiv, Ukraine.
<https://orcid.org/0000-0001-6335-2490>

^{6,3}Marika Sulashvili, MD, Invited Lecturer; Tbilisi, Georgia. <https://orcid.org/0000-0002-6338-4262>

⁹Nato Alavidze; Kutaisi, Georgia. <https://orcid.org/0000-0001-6695-5924>

¹Ia Egnatievi , MD, PhD, Professor; Tbilisi, Georgia.

¹Manana Giorgobiani, MD, PhD, Professor; Tbilisi, Georgia.

¹⁰Magda Davitashvili , PhD, Professor, Academician, Telavi, Georgia. <https://orcid.org/0009-0005-4213-6533>

⁴Irina Imerlishvili, PhD, Doctor of Law, Professor; Batumi, Georgia.

⁶Marina Giorgobiani, Academician, Professor; Tbilisi, Georgia. <https://orcid.org/0000-0003-0686-5227>

⁸Igor Seniuk, PhD, , Associate Professor, Kharkiv, Ukraine. <https://orcid.org/0000-0003-3819-7333>

^{5,11}Lali Patsia, MD, PhD, Professor; Tbilisi, Georgia.

⁸Olga Shapoval, Professor; Kharkiv, Ukraine <https://orcid.org/0000-0002-1971-2863>

⁶Natia Kvizhinadze , PhD, Professor; Tbilisi, Georgia.

⁶Lasha Tchelidze, MD, PhD student;

¹²David Aphkhazava, PhD, Professor, Tbilisi, Georgia. <https://orcid.org/0000-0001-6216-6477>

¹David Aghmashenebeli University of Georgia, ²Georgian International University GIU, ³Georgian National University SEU, ⁴BAU International University Batumi, ⁵Alte University, ⁶Tbilisi State Medical University; ⁷Yerevan State Medical University After Mkhitar Herats, ⁸National University of Pharmacy of Ukraine, Kharkiv, ⁹Akaki Tsereteli State University, ¹⁰Iakob Gogebashvili Telavi State University, ¹¹Ken Walker international University, ¹²University of Georgia.

Corresponding Author: Dr. Professor Nodar Sulashvili

Mail: n.sulashvili@ug.edu.ge

Mob: +995-597-12-17-28

Abstract

Drug discovery has evolved from a largely empirical discipline into a knowledge-intensive enterprise that depends on the integration of pharmacology, structural biology, computational chemistry, and bioinformatics. Modern pharmacotherapeutic design is no longer satisfied by the demonstration that a molecule binds a macromolecular target. Instead, a candidate must be considered within a broader context that includes disease mechanism, network position of the target, tissue expression, structural tractability, off-target liabilities, pharmacokinetic behavior, and the probability of translation from preclinical systems to humans. Bioinformatic analysis has become central to this process because it enables the organization and interpretation of genomic, transcriptomic, proteomic, metabolomic, phenotypic, and chemical data at a scale that cannot be managed by traditional reductionist workflows alone. Pharmacology remains equally indispensable because the relevance of computational outputs depends on mechanistic interpretation, exposure-response understanding, and a realistic view of efficacy and safety in complex biological systems. This review examines how pharmacology and bioinformatic analysis jointly inform contemporary drug design across the discovery pipeline. It discusses target identification and validation, structural bioinformatics, structure-based and ligand-based design, network pharmacology, multi-omics analysis, ADMET prediction, and pharmacokinetic-pharmacodynamic modeling. It also addresses the increasing role of machine learning, not as a replacement for experimental science, but as a tool for prioritization, pattern recognition, and iterative decision support. Particular emphasis is placed on the limitations of current approaches, including database incompleteness, bias in training sets, uncertain biological annotation, and the common error of overinterpreting docking scores or predictive probabilities as proof of therapeutic success. The central argument is that the most reliable drug design strategies

emerge when computational breadth is combined with pharmacological depth. In that integrative framework, bioinformatics helps define what should be tested, while pharmacology determines what the resulting signals actually mean for drug action, safety, and translation.

Keywords: Pharmacology; bioinformatics; drug design; structure-based drug discovery; systems pharmacology; molecular dynamics; multi-omics; pharmacokinetic-pharmacodynamic modeling;

ფარმაკოლოგია და ბიოინფორმატიკული ანალიზი თანამედროვე მედიკამენტების დიზაინში: სამიზნეების აღმოჩენიდან ტრანსლაციურ ოპტიმიზაციამდე ინტეგრირებული მოლეკულური, კომპიუტაციული, სტრუქტურული, სისტემური და პერსონალიზებული მედიცინის მიდგომების საფუძველზე

^{1,2,3,4,5,6}ნოდარ სულაშვილი, მედიცინის დოქტორი (MD, PhD), პროფესორი. თბილისი, საქართველო. <https://orcid.org/0000-0002-9005-8577>

⁷მარგარიტა ბეგლარიანი, მედიცინის დოქტორი (MD, PhD), აკადემიკოსი, პროფესორი. ერევანი, სომხეთი; <https://orcid.org/0000-0003-3697-6390>

⁸ნანა გორგასლიძე, მედიცინის დოქტორი (MD, PhD), პროფესორი. თბილისი, საქართველო. <https://orcid.org/0000-0002-4563-5224>

⁷ნაირა ჩიჩოიანი, მედიცინის დოქტორი (MD, PhD), პროფესორი. ერევანი, სომხეთი. <https://orcid.org/0000-0003-3905-3372>

⁸ვირა კრავჩენკო, მედიცინის დოქტორი (MD, PhD), აკადემიკოსი, პროფესორი. ხარკივი, უკრაინა. <https://orcid.org/0000-0001-6335-2490>

^{6,3}მარიკა სულაშვილი, მედიცინის დოქტორი (MD), მოწვეული ლექტორი. თბილისი, საქართველო. <https://orcid.org/0000-0002-6338-4262>

⁹ნატო ალავიძე, ქუთაისი, საქართველო. <https://orcid.org/0000-0001-6695-5924>

¹ია ეგნატიევი, მედიცინის დოქტორი (MD, PhD), პროფესორი

¹მანანა გიორგობიანი, მედიცინის დოქტორი (MD, PhD), პროფესორი, თბილისი, საქართველო.

¹⁰მაგდა დავითაშვილი, დოქტორი (PhD), პროფესორი, აკადემიკოსი, თელავი, საქართველო. <https://orcid.org/0009-0005-4213-6533>

⁴ირინა იმერლიშვილი, დოქტორი (PhD), სამართლის დოქტორი, პროფესორი; თბილისი, საქართველო.

⁶მარინა გიორგობიანი, აკადემიკოსი, პროფესორი; თბილისი, საქართველო. <https://orcid.org/0000-0003-0686-5227>

⁸იგორ სენიუკი, დოქტორი, ასოცირებული პროფესორი, ხარკივი, უკრაინა. <https://orcid.org/0000-0003-3819-7333>

^{5,11}ლალი ფაცია, მედიცინის დოქტორი, პროფესორი; თბილისი, საქართველო..

⁸ოლგა შაპოვალაი, პროფესორი; ხარკივი, უკრაინა; <https://orcid.org/0000-0002-1971-2863>

⁶ნათია კვიფინაძე, დოქტორი, პროფესორი; თბილისი, საქართველო.

ლამა ჭელიძე, დოქტორანტი; თბილისი, საქართველო.

¹²დავით აფხაზავა, დოქტორი, პროფესორი; თბილისი, საქართველო.

<https://orcid.org/0000-0001-6216-6477>

აბსტრაქტი

სამკურნალო საშუალებების აღმოჩენის პროცესი ძირითადად ემპირიულ დისციპლინად ჩამოყალიბებული სფეროდან გადაიქცა ცოდნაზე ინტენსიურად დაფუძნებულ კომპლექსურ სამეცნიერო მიმართულებად, რომელიც ეყრდნობა ფარმაცოლოგიის, სტრუქტურული ბიოლოგიის, კომპიუტაციური ქიმიისა და ბიოინფორმატიკის ინტეგრაციას. თანამედროვე ფარმაცოთერაპიული დიზაინი აღარ შემოიფარგლება მხოლოდ იმის დემონსტრირებით, რომ კონკრეტული მოლეკულა უკავშირდება მაკრომოლეკულურ სამიზნეს. ამის ნაცვლად, სამკურნალწამლო პრეპარატის კანდიდატი მოლეკულა უნდა შეფასდეს უფრო ფართო კონტექსტში, რომელიც მოიცავს დაავადების მექანიზმს, სამიზნის ფუნქციურ პოზიციას, ქსოვილოვან ექსპრესიას, სტრუქტურულ შესწავლადობას, არასამიზნე ურთიერთქმედებით განპირობებულ პოტენციურ რისკებს, ფარმაცოკინეტიკურ მახასიათებლებს და პრეკლინიკური სისტემებიდან ადამიანებში მიღებული შედეგების ტრანსლაციის ალბათობას. ბიოინფორმატიკური ანალიზი აღნიშნულ პროცესში ცენტრალურ მნიშვნელობას იძენს, რადგან იგი შესაძლებელს ხდის გენომური, ტრანსკრიპტომული, პროტეომული, მეტაბოლომური, ფენოტიპური და ქიმიური მონაცემების ისეთი მასშტაბით ორგანიზებასა და ინტერპრეტაციას, რომლის მართვა მხოლოდ ტრადიციული რედუქციონისტული მიდგომებით შეუძლებელია. ამასთანავე, ფარმაცოლოგია კვლავ შეუცვლელ კომპონენტად რჩება, ვინაიდან კომპიუტაციური ანალიზის შედეგების მნიშვნელობა დამოკიდებულია მათ მექანიკურ ინტერპრეტაციაზე, ექსპოზიცია-პასუხის ურთიერთკავშირის გააზრებასა და რთულ ბიოლოგიურ სისტემებში ეფექტიანობისა და უსაფრთხოების რეალისტურ შეფასებაზე. წინამდებარე მიმოხილვა განიხილავს, თუ როგორ უზრუნველყოფს ფარმაცოლოგიისა და ბიოინფორმატიკური ანალიზის ერთობლივი გამოყენება თანამედროვე სამკურნალო საშუალებების დიზაინის მეცნიერულ საფუძველს პრეპარატის აღმოჩენის მთელ პროცესში. განხილულია სამიზნის იდენტიფიკაცია და ვალიდაცია, სტრუქტურული ბიოინფორმატიკა, სტრუქტურაზე დაფუძნებული და ლიგანდზე დაფუძნებული დიზაინი, ქსელური ფარმაცოლოგია, მულტიომიკური ანალიზი, ADMET-პროგნოზირება და ფარმაცოკინეტიკურ-ფარმაცოდინამიკური მოდელირება. ასევე განხილულია მანქანური სწავლების მზარდი როლი, არა ექსპერიმენტული მეცნიერების შემცვლელის, არამედ კანდიდატების პრიორიტეტიზაციის, კანონზომიერებების ამოცნობისა და გადაწყვეტილების მიღების განმეორებითი მხარდაჭერის ინსტრუმენტის სახით. განსაკუთრებული ყურადღება ეთმობა თანამედროვე მიდგომების შეზღუდვებს, მათ შორის მონაცემთა ბაზების არასრულყოფილებას, სასწავლო მონაცემთა ნაკრებების მიკერძოებულობას, ბიოლოგიური ანოტაციის გაურკვევლობას და გავრცელებულ მეთოდოლოგიურ შეცდომას — დოკინგის ქულების ან პროგნოზული ალბათობების თერაპიული წარმატების დამადასტურებელ მტკიცებულებად გადაჭარბებულ

ინტერპრეტაციას. ძირითადი არგუმენტი მდგომარეობს იმაში, რომ სამკურნალო საშუალებების დიზაინის ყველაზე სანდო სტრატეგიები ყალიბდება მაშინ, როდესაც კომპიუტაციური ანალიზის ფართო შესაძლებლობები ერთიანდება ფარმაცოლოგიურ სიღრმესთან. ამ ინტეგრაციულ ჩარჩოში ბიოინფორმატიკა განსაზღვრავს, რა უნდა შემოწმდეს, ხოლო ფარმაცოლოგია ადგენს, რას ნიშნავს მიღებული სიგნალები რეალურად პრეპარატის მოქმედების, უსაფრთხოებისა და კლინიკური ტრანსლაციის თვალსაზრისით.

საკვანძო სიტყვები: ფარმაცოლოგია; ბიოინფორმატიკა; მედიკამენტების დიზაინი; სტრუქტურაზე დაფუძნებული მედიკამენტების აღმოჩენა; სისტემური ფარმაცოლოგია; მოლეკულური დინამიკა; მულტი-ომიკური ანალიზი; ფარმაცოკინეტიკურ-ფარმაცოდინამიკური მოდელირება.

Introduction

The scientific landscape of modern pharmacology and drug discovery has undergone a profound transformation from empirically driven compound screening toward an increasingly integrated, data-intensive, mechanism-oriented discipline. Historically, the identification of therapeutic agents relied heavily on phenotypic observations, natural-product exploration, serendipitous discoveries, and sequential biological testing. Although these approaches generated numerous clinically important medicines, they were frequently associated with prolonged development timelines, high attrition rates, incomplete understanding of molecular mechanisms, and substantial financial investment. Contemporary drug design increasingly addresses these limitations through the convergence of pharmacology, molecular biology, structural biology, computational chemistry, bioinformatics, systems pharmacology, artificial intelligence, pharmacogenomics, and precision medicine. Within this interdisciplinary framework, bioinformatic analysis has become an essential component of target identification, molecular characterization, compound prioritization, mechanistic prediction, biomarker discovery, and translational optimization [5,12,17,68].

Pharmacology provides the conceptual and experimental foundation for understanding how therapeutic agents interact with biological systems. At its core, pharmacology examines the relationships among drug concentration, molecular target engagement, cellular signaling, physiological responses, therapeutic efficacy, and adverse effects. Pharmacodynamics describes how drugs influence biological systems, whereas pharmacokinetics characterizes the processes governing absorption, distribution, metabolism, and excretion. Modern pharmacology extends beyond these classical domains by incorporating receptor pharmacology, molecular pharmacology, pharmacogenomics, pharmacometabolomics, systems pharmacology, network pharmacology, and quantitative pharmacology. These developments have made it increasingly clear that the clinical effects of a drug cannot always be explained by a single molecular interaction. Rather, therapeutic responses emerge from complex interactions among targets, signaling pathways, metabolic processes, cellular phenotypes, tissue environments, genetic variation, and disease-associated molecular networks [62,65,69].

Bioinformatics provides a complementary analytical framework capable of organizing and interpreting the enormous quantities of biological information generated through contempo-

rary experimental technologies. Genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, structural databases, molecular interaction networks, and high-throughput screening have produced extensive multidimensional datasets. The challenge is no longer simply to generate biological information but to transform heterogeneous data into mechanistic knowledge that can guide rational therapeutic development. Bioinformatic methodologies facilitate sequence analysis, structural prediction, molecular annotation, pathway reconstruction, protein–protein interaction analysis, target prioritization, biomarker identification, comparative genomics, evolutionary analysis, and computational prediction of drug–target interactions. Consequently, bioinformatics has become deeply integrated with pharmacological reasoning and now constitutes a major component of modern drug-discovery strategies [24,41,75].

One of the most important applications of integrated pharmacology and bioinformatics is target discovery. A drug target should not merely demonstrate biological relevance; it should possess sufficient mechanistic, structural, pharmacological, and translational validity to justify therapeutic intervention. Target identification therefore requires evaluation of disease-associated molecular alterations, functional significance, tissue and cellular expression, pathway involvement, genetic evidence, structural tractability, druggability, and potential safety liabilities. Genomic and transcriptomic datasets can reveal genes differentially expressed in disease states, whereas proteomic and metabolomic approaches can identify alterations occurring at functional molecular levels. Integration of these datasets through bioinformatic pipelines can identify candidate targets that occupy critical positions within pathological signaling networks. Such approaches are particularly valuable for complex diseases in which pathological phenotypes arise from interactions among numerous genes and pathways rather than from a single defective molecular component [28,63,57].

Network pharmacology has further expanded the conceptual framework of target discovery by emphasizing the interconnected nature of biological systems. Conventional drug-development paradigms have often focused on a linear relationship between a drug, a target, and a clinical effect. In contrast, network-based approaches recognize that a single compound may interact with multiple molecular targets and that individual targets may participate in multiple signaling pathways. Polypharmacology can therefore contribute to therapeutic efficacy, particularly in multifactorial disorders, while simultaneously increasing the possibility of off-target toxicity. Bioinformatic network analysis allows researchers to construct and interrogate molecular interaction networks, identify highly connected nodes, characterize disease-associated modules, and predict potential drug–target relationships. This systems-level perspective supports a more comprehensive interpretation of pharmacological activity and can facilitate the identification of therapeutic combinations and multitarget strategies [63,68,74]. Structural biology represents another essential component of contemporary drug design. Knowledge of three-dimensional molecular structures enables researchers to investigate ligand-binding sites, conformational states, catalytic domains, allosteric regions, protein flexibility, and intermolecular interactions. Experimental approaches such as X-ray crystallography, nuclear magnetic resonance spectroscopy, and cryo-electron microscopy have generated extensive structural information, while computational approaches have substantially expanded the ability to predict protein structures and molecular conformations. Structural bioinformatics enables the analysis and comparison of protein structures, identification of binding pockets, evaluation of conserved and variable residues, and characterization of ligand–

protein interactions. These capabilities have strengthened structure-based drug design and facilitated the development of molecules with improved potency, selectivity, and pharmacological profiles [16,24,39].

Molecular docking and virtual screening are particularly important computational strategies within structure-based drug discovery. Molecular docking estimates potential binding orientations between candidate ligands and macromolecular targets, whereas virtual screening permits large chemical libraries to be computationally evaluated before experimental testing. Such approaches can reduce the number of compounds requiring laboratory investigation and thereby improve the efficiency of lead identification. Nevertheless, docking scores should not be interpreted as definitive evidence of biological activity. Protein flexibility, solvent effects, entropic contributions, binding kinetics, and cellular context can substantially influence drug–target interactions. Therefore, docking is most valuable when integrated with experimental pharmacology, molecular dynamics simulations, biochemical assays, and appropriate validation strategies [48,65,67].

Molecular dynamics simulations have further advanced the characterization of dynamic drug–target interactions. Unlike static structural models, molecular dynamics can investigate conformational fluctuations, protein flexibility, ligand stability, binding-site rearrangements, and solvent-mediated interactions over time. These analyses are particularly relevant for receptors, ion channels, enzymes, and other dynamic macromolecules in which biologically important conformations may not be adequately represented by a single experimentally determined structure. Integration of molecular dynamics with pharmacological and structural data can improve understanding of binding mechanisms and support the optimization of ligand affinity, selectivity, residence time, and allosteric modulation.

Artificial intelligence and machine learning have accelerated this transition toward data-driven drug discovery. Machine-learning algorithms can identify complex relationships within high-dimensional datasets that may be difficult to detect through conventional statistical methods. Applications include virtual screening, quantitative structure–activity relationship modeling, toxicity prediction, drug–target interaction prediction, de novo molecular generation, pharmacokinetic prediction, molecular property optimization, and biomarker discovery. Deep-learning architectures can analyze molecular graphs, chemical fingerprints, protein sequences, three-dimensional structures, and multimodal biological datasets. Generative models additionally provide opportunities for designing novel molecular structures according to predefined pharmacological and physicochemical constraints. However, computational performance alone does not establish therapeutic validity. Models require appropriate training datasets, external validation, interpretability, prospective testing, and experimental confirmation [38,39,67].

An important objective of modern drug design is therefore the integration of computational predictions with experimental pharmacology. Computational models can prioritize hypotheses, but pharmacological experimentation establishes whether predicted interactions translate into measurable biological effects. In vitro receptor-binding assays, enzyme inhibition studies, cellular signaling experiments, functional assays, and phenotypic screening remain essential for determining pharmacological activity. Subsequently, animal models and translational studies provide information regarding pharmacokinetics, pharmacodynamics, efficacy, toxicity, and tissue distribution. The most effective contemporary workflows consequently operate as iterative cycles in which computational predictions guide experiments, experimental

observations refine computational models, and validated biological information informs subsequent molecular optimization [47,49,57,64].

Pharmacokinetic and pharmacodynamic considerations are increasingly incorporated at earlier stages of drug design. Traditional discovery programs sometimes emphasized potency against a molecular target without sufficiently considering whether an optimized compound could achieve adequate exposure at the relevant anatomical site. Modern approaches seek to integrate absorption, distribution, metabolism, excretion, and toxicity characteristics with pharmacological potency. Quantitative structure–property relationships, physiologically based pharmacokinetic modeling, quantitative systems pharmacology, and pharmacokinetic–pharmacodynamic modeling can help predict concentration–effect relationships and identify dose-limiting factors. Bioinformatic analysis of metabolic enzymes, transporters, and pharmacokinetic pathways can further contribute to the prediction of drug disposition and drug–drug interactions [51,56,64].

The emergence of pharmacogenomics has strengthened the connection between molecular drug design and precision medicine. Genetic variation among individuals can influence drug metabolism, transport, receptor sensitivity, immune responses, efficacy, and toxicity. Pharmacogenomic analysis can identify genetic determinants associated with therapeutic response and adverse drug reactions, thereby supporting patient stratification and individualized treatment. In this context, modern drug discovery is increasingly concerned not only with identifying an effective molecule but also with identifying the biological populations most likely to benefit from that molecule. Biomarker-driven development can improve clinical-trial design, reduce heterogeneity, and facilitate more precise evaluation of therapeutic efficacy [28,39,63].

Precision medicine consequently represents a major translational extension of integrated pharmacology and bioinformatics. Disease classification based exclusively on anatomical diagnosis or conventional clinical phenotypes may obscure substantial molecular heterogeneity. Two patients with the same clinical diagnosis may possess different genetic alterations, signaling abnormalities, immune profiles, metabolic states, or drug-response mechanisms. Multi-omics analysis can characterize this heterogeneity and support molecularly informed patient stratification. Integration of genomics, transcriptomics, proteomics, metabolomics, clinical phenotypes, and pharmacological data may therefore facilitate the identification of disease subtypes and therapeutic vulnerabilities that remain invisible through conventional approaches [16,55,68].

The concept of translational optimization is particularly important because successful drug discovery requires more than molecular novelty. A candidate drug must demonstrate an appropriate balance among target engagement, selectivity, efficacy, safety, pharmacokinetics, manufacturability, and clinical feasibility. Bioinformatic approaches can contribute to each of these dimensions by identifying potential liabilities before substantial resources are committed to development. Computational toxicology can predict interactions associated with adverse effects; genomic analysis can reveal potential safety concerns; structural analysis can identify unintended binding sites; and network-based approaches can characterize downstream pathway perturbations. Early identification of such liabilities may prevent costly late-stage failures [37,62,67].

Another important development is the increasing integration of real-world and clinical data with molecular pharmacology. Electronic health records, clinical databases, pharmacovigilance systems, and population-level datasets provide information about drug effectiveness and safety under heterogeneous clinical conditions. When appropriately analyzed, these resources can complement experimental and computational data. Pharmacovigilance databases can reveal rare adverse drug reactions, while clinical data can identify patterns of treatment response that generate new mechanistic hypotheses. Integration of clinical observations with molecular and bioinformatic datasets represents an important step toward a continuously learning drug-development ecosystem.

Despite these advances, significant challenges remain. Biological systems are highly complex, dynamic, context-dependent, and incompletely characterized. Computational models can be affected by biased datasets, incomplete annotations, inappropriate assumptions, and insufficient external validation. Molecular docking may produce false-positive predictions, machine-learning models may suffer from data leakage or poor generalizability, and network analyses may identify associations that do not represent causal biological mechanisms. Furthermore, the reproducibility and interpretability of computational predictions remain critical concerns. Therefore, computational sophistication must be accompanied by rigorous experimental validation, transparent methodology, appropriate statistical analysis, and careful consideration of biological plausibility [15,29,64].

The integration of pharmacology and bioinformatics also raises important methodological and ethical considerations. Large-scale biomedical datasets may contain sensitive patient information, requiring appropriate governance, anonymization, cybersecurity, and regulatory oversight. Artificial intelligence systems used for clinical decision-making must be evaluated for reproducibility, bias, explainability, and clinical validity. Moreover, equitable access to precision therapeutics remains an important societal challenge because advanced molecular diagnostics and individualized treatments may require substantial technological and financial resources.

The convergence of pharmacology and bioinformatic analysis represents a fundamental paradigm shift in modern drug design. The contemporary discovery process increasingly connects molecular target identification with structural characterization, computational screening, systems-level analysis, pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, biomarker discovery, and precision medicine. Rather than treating these disciplines as independent stages, modern drug development increasingly conceptualizes them as interconnected components of a continuous translational framework. Such integration can accelerate the identification of therapeutically relevant targets, improve molecular optimization, anticipate pharmacological and toxicological liabilities, and enhance the probability that promising discoveries will successfully transition from computational prediction and experimental validation to clinical application [3,18,59].

The scientific discourse surrounding modern drug design therefore reflects a broader transformation in biomedical science: from reductionist, target-centered discovery toward multi-dimensional, data-driven, systems-oriented, and patient-centered therapeutic development. Pharmacology remains indispensable for establishing causal relationships between molecular intervention and biological response, while bioinformatics provides the analytical infrastructure required to interpret increasingly complex biological datasets. Structural biology clarifies

molecular architecture; computational chemistry predicts interactions; systems pharmacology explains network-level consequences; pharmacogenomics identifies interindividual variation; and precision medicine translates molecular information into individualized therapeutic strategies. Their convergence provides a scientifically coherent framework for moving from target discovery to translational optimization and ultimately toward safer, more effective, and more precisely tailored medicines. The future of drug discovery will therefore depend not on any single technology, but on the rigorous integration of experimental pharmacology, computational intelligence, molecular and structural science, systems biology, clinical evidence, and precision-oriented therapeutic reasoning.


The cost, duration, and attrition associated with drug development continue to motivate more rational discovery strategies. Despite major advances in chemical synthesis, assay technology, and disease biology, only a small proportion of drug candidates entering development eventually become approved medicines. Analyses of research and development productivity have shown that failure often reflects inadequate efficacy, unanticipated toxicity, suboptimal pharmacokinetics, poor target selection, or weak translational logic rather than simple lack of chemical novelty [1,3]. As a result, the quality of early scientific decisions now carries greater weight than the quantity of compounds synthesized or screened. This shift has elevated pharmacology and bioinformatics into complementary pillars of modern drug design.

Results and Discussion

Pharmacology contributes the conceptual framework needed to understand how molecules interact with biological systems. It defines potency, efficacy, selectivity, receptor reserve, signal amplification, temporal dynamics, on-target and off-target effects, therapeutic index, and exposure-response relationships. These concepts remain crucial even when discovery workflows are computationally driven, because a predicted interaction has little value unless it can be interpreted in terms of mechanism and therapeutic intent [2,25,27]. Bioinformatics, by contrast, offers scale, integration, and pattern detection. It allows investigators to mine disease datasets, connect targets to pathways, identify expression signatures, compare diseased and healthy states, infer networks, and prioritize hypotheses that would be impractical to generate manually [5-9,18-24].

The merger of these disciplines has transformed drug design from a linear sequence into a cyclical knowledge system. A target may be nominated from transcriptomic data, evaluated by network centrality, mapped to structural information from experimental or predicted models, screened against large chemical libraries *in silico*, refined through medicinal chemistry and ADMET forecasting, and finally interpreted through pharmacokinetic-pharmacodynamic models that determine whether the proposed mechanism is likely to be sustained at clinically feasible exposures [8-17,25-35]. Importantly, these steps are not independent. Bioinformatic outputs influence pharmacological experimentation, while pharmacological findings recalibrate computational models. The most effective discovery programs now depend on this reciprocity.

This article reviews the major intersections between pharmacology and bioinformatic analysis in drug design. Rather than treating computational methods as an autonomous solution, it argues that their value depends on disciplined integration with mechanistic pharmacology, rigorous data curation, and realistic translational thinking. Such integration is increasingly necessary as discovery moves toward multi-target intervention, precision



medicine, and data-dense therapeutic platforms (Fig 1).

Figure 1. Integrative framework of pharmacology and bioinformatics in modern drug design. Two complementary pillars, Bioinformatics (data scale, integration, pattern recognition) and Pharmacology (mechanism, exposure-response, efficacy and safety), feed into a six-stage Integrative Cycle: target nomination and prioritisation, informed by transcriptomic and genomic data; network analysis and pathway context, which integrates centrality and pathway modules; structural bioinformatics for pocket detection and modelling; virtual screening and molecular dynamics, encompassing docking, MD, QSAR and ML; ADMET prediction of pharmacokinetics and toxicity; and PK/PD modelling and translation, evaluated through exposure-response relationships and the therapeutic index. The arrows between adjacent stages emphasise that the workflow is cyclic rather than linear: bioinformatic outputs direct pharmacological hypotheses, while pharmacological data recalibrate the computational models. Each coloured frame auto-sizes to the measured width and height of its enclosed text, so no label overflows or overlaps its container.

Pharmacological Foundations of Rational Drug Design

Rational drug design begins with a pharmacological question rather than a purely computational one: what aspect of disease biology should be modulated, by what degree, in which tissue, over what duration, and with what tolerable liabilities? That question shapes

the entire discovery program. A protein that appears statistically associated with disease may still be a poor target if its modulation produces only modest downstream effects, if compensatory pathways buffer the intervention, or if therapeutically relevant engagement would require exposures that compromise safety. For this reason, target selection cannot be divorced from mechanism-based pharmacology [2,22,23].

Classical pharmacological principles remain deeply relevant in the age of bioinformatics. Affinity alone does not guarantee efficacy, particularly for targets embedded in nonlinear signaling networks. Partial agonism, biased signaling, allosteric modulation, residence time, and target turnover all influence whether a ligand will produce a clinically useful effect [2,25]. Similarly, selectivity must be considered in biological rather than purely biochemical terms. Some off-target activities are unacceptable because they widen toxicity risk, whereas others can contribute to efficacy in polygenic disease states. Network pharmacology has renewed appreciation for this point by showing that many successful drugs produce their effects through coordinated perturbation of several nodes rather than perfect specificity for a single protein [22,23].

The modern emphasis on translational pharmacology also means that drug design should consider exposure and tissue distribution from the earliest stages. A potent inhibitor is not a plausible medicine if it cannot reach the relevant compartment, is rapidly cleared, accumulates in the wrong tissue, or requires concentrations associated with mechanism-independent toxicity [13-16,25-27]. Early pharmacological thinking therefore improves the quality of bioinformatic prioritization. When transcriptomic analyses identify dozens of possible disease-associated genes, targets can be filtered according to druggability, expected direction of modulation, availability of pharmacodynamic biomarkers, and the feasibility of maintaining meaningful target engagement in vivo.

A further implication is that pharmacology helps prevent overconfidence in computational surrogates. Virtual screening, network ranking, and machine learning classification can identify promising candidates, but they do not in themselves establish target vulnerability or therapeutic relevance. Experimental pharmacology remains the bridge between prediction and intervention. In practice, the strongest discovery programs use bioinformatics to reduce the hypothesis space and pharmacology to interrogate causality, reversibility, and dose dependence. This division of labor is neither old-fashioned nor conservative. It is the basis for making computationally informed decisions that remain biologically and clinically credible.

Bioinformatic Data Layers for Target Discovery and Prioritization


Target identification increasingly depends on the coordinated analysis of public and proprietary data resources. Databases such as DrugBank and ChEMBL provide curated information on approved drugs, investigational compounds, binding affinities, functional activities, physicochemical properties, metabolism, and mechanism annotations [5,6]. STRING and Cytoscape support the examination of protein association networks and facilitate the contextualization of candidate targets within pathways, complexes, and disease modules [7,21]. These resources are most useful when treated not as static repositories but as interoperable evidence layers that can be cross-examined against experimental findings.

A common starting point in contemporary discovery is differential expression analysis or disease signature mining. Transcriptomic comparisons between diseased and normal tissues

can reveal genes that are consistently dysregulated, while gene set enrichment analysis helps determine whether these changes converge on biological processes of pharmacological interest such as inflammation, cell-cycle control, metabolism, stress signaling, or immune activation [18,20]. The Connectivity Map extended this logic by enabling comparison between disease signatures and compound-induced transcriptional responses, creating opportunities for both mechanism inference and drug repurposing [19]. Such analyses can identify candidate targets directly, but they often have greater value in defining disease states that should be reversed or stabilized.

Network-based prioritization adds another dimension. A target whose expression changes modestly may still be attractive if it occupies a central regulatory position, connects multiple disease-relevant pathways, or functions within a vulnerable module that lacks redundancy [7,22,23]. Conversely, highly dysregulated genes are not always good targets if they are downstream markers rather than control points. Bioinformatic workflows therefore increasingly combine expression, network topology, genetic association, essentiality screens, and prior tractability evidence. Cancer dependency datasets, CRISPR screens, and genotype-phenotype resources have been especially useful in distinguishing drivers from passengers and in clarifying context-specific vulnerabilities [36,40].

However, data integration requires caution. Databases vary in curation depth, update frequency, assay standardization, and annotation logic. Drug-target networks are especially sensitive to missing data and publication bias, and even highly cited repositories remain



incomplete [24]. Disease signatures are also influenced by tissue composition, sampling time, treatment status, and platform-specific normalization. For this reason, target prioritization should not rely on any single analytic layer. The most robust strategies triangulate across orthogonal evidence streams and reserve highest confidence for targets supported by convergent biological, structural, and pharmacological signals (Fig.2).

Figure 2. Multi-evidence triangulation for target prioritisation in modern drug discovery. The flow begins with the disease phenotype and unmet need — the question that target identification must ultimately answer — and proceeds downward through five orthogonal bioinformatic evidence layers, each interrogated by dedicated resources: Expression and transcriptomic dysregulation, supported by differential expression, gene set enrichment, and the Connectivity Map; Network topology and pathway centrality, supported by STRING, Cytoscape, pathway modules, and interactomes; Chemical knowledge and ligand evidence, supported by DrugBank and ChEMBL bioactivities and mechanism annotations; Genetic and dependency evidence, supported by GWAS, genotype–phenotype associations, CRISPR screens, and cancer dependency maps; and Structural tractability and druggability, supported by pocket detection, predicted models, prior pharmacology, and selectivity context. Each layer alone is incomplete; convergent signals across layers raise confidence and feed into the central Triangulation across orthogonal evidence node. The output is then passed through a Pharmacological filter — tractable target type, expected direction of modulation, availability of a pharmacodynamic biomarker, feasibility of in vivo engagement, and tissue exposure with safety — to yield Prioritised target candidates ready for the integrative cycle of experimental validation, medicinal chemistry, ADMET prediction, and PK/PD modelling [41-44].

Structural Bioinformatics and Target Tractability

Structural bioinformatics has become one of the defining enablers of modern drug design because it helps convert biological interest into chemically actionable hypotheses. Historically, structure-based discovery depended heavily on experimentally solved structures derived from X-ray crystallography, NMR spectroscopy, or cryo-electron microscopy. These methods remain foundational, but the availability of large-scale structural resources has expanded dramatically through platforms such as the AlphaFold Protein Structure Database and through advances in predictive modeling more generally [8,9]. As a result, many proteins that were once considered opaque to rational design can now be examined for fold architecture, ligandable pockets, domain organization, conformational constraints, and residue environments relevant to selectivity.

Target tractability is not determined by the presence of a structure alone. A useful structural model must support meaningful hypotheses about ligand binding, allostery, induced fit, or interface disruption. Some proteins present deep, well-defined pockets suited to small-molecule inhibition, whereas others display shallow surfaces, dynamic conformations, or context-dependent binding sites that complicate discovery. Structural bioinformatics helps distinguish these cases. Pocket detection, conservation mapping, water analysis, conformational sampling, and comparative modeling can reveal whether a target is likely to support orthosteric ligands, allosteric modulators, covalent agents, or perhaps degraders rather than classical occupancy-based inhibitors [8-12].

Predicted structures have had a particularly important effect on early hypothesis generation. AlphaFold-quality models do not eliminate uncertainty, especially in flexible loops, multimeric assemblies, or intrinsically disordered regions, but they often provide enough information to guide mutagenesis, domain boundary interpretation, and exploratory docking [8,9]. In drug design, their greatest value may lie in reducing the number of targets considered structurally inaccessible. When combined with sequence conservation analysis and known ligand information from related proteins, predicted structures can reveal tractability that would otherwise remain hidden.

Yet structural bioinformatics is also a domain where overconfidence is common. Predicted pocket geometry can be misleading, static structures may obscure biologically important conformational ensembles, and homology-based assumptions can underestimate the subtle determinants of subtype selectivity. Therefore, tractability assessments are strongest when structural inference is coupled with pharmacological questions: what state of the protein is functionally relevant, what degree of occupancy is required, what kinetic profile is desirable, and how might mutations, cofactors, membranes, or partner proteins alter the binding landscape? Structural information is most powerful not when treated as a final answer, but when used to formulate experimentally testable models of drug action [45–48].

Structure-Based Drug Design: Docking, Dynamics, and Virtual Screening

Structure-based drug design seeks to exploit knowledge of the three-dimensional target architecture in order to identify or optimize ligands with desirable binding properties. Molecular docking remains a central technique in this area because it allows rapid exploration of candidate binding poses and approximate ranking of compounds according to fit within a target site [10,11,28]. In practical discovery programs, docking is rarely used as a stand-alone decision tool. Instead, it functions as an early prioritization layer that narrows large chemical spaces before biochemical assays, biophysical validation, and medicinal chemistry refinement.


The utility of docking depends on realistic expectations. Docking programs approximate a complex physical process involving solvation, entropy, conformational adaptation, and sometimes multiple protonation or tautomeric states. A high docking score may reflect favorable geometric complementarity without corresponding biological activity, while a mediocre score can still identify a chemically tractable series if the pose captures a relevant interaction pattern [10,28]. For that reason, experienced practitioners typically interpret docking results alongside known structure-activity relationships, conserved contacts, ligand efficiency, synthetic feasibility, and orthogonal pharmacological evidence. Enrichment and triage are more reliable goals than literal ranking of absolute affinity.

Virtual screening has scaled dramatically with improvements in computational infrastructure. Ultra-large library screening platforms have shown that hundreds of millions to billions of compounds can now be prepared and evaluated through automated workflows, allowing medicinal chemists to access chemical diversity previously unreachable by conventional screening campaigns [29]. This expansion is valuable because chemically novel matter is often required to achieve improved selectivity, patentability, or physicochemical balance. Nevertheless, the size of a screening library does not compensate for poor target choice, inadequate receptor preparation, or implausible hit triage criteria. Screening quality

still depends on the validity of the biological question and the rigor of follow-up evaluation [49-51].

Molecular dynamics simulations address some of the shortcomings of static docking by sampling the motion of proteins and complexes over time [12]. These simulations help identify transient pockets, evaluate pose stability, investigate water-mediated interactions, and explore conformational states that may be critical for activity or selectivity. Dynamics can be especially informative when receptor flexibility influences ligand recognition, as occurs with kinases, GPCRs, and allosteric enzymes. They also support mechanistic interpretation by revealing how binding perturbs networks of residues rather than simply occupying a cavity.

In modern workflows, docking and dynamics are increasingly integrated with free-energy estimation, fragment elaboration, and machine-learning-guided prioritization [10-12,29,30]. Yet the underlying pharmacological principle remains unchanged: computational binding hypotheses must be anchored to biological function. A beautifully docked ligand that fails to produce the desired cellular phenotype, target engagement pattern, or exposure profile is not a lead. Structure-based methods are most powerful when they accelerate the path toward



mechanistically meaningful compounds rather than when they are mistaken for a substitute for pharmacological reality.

Figure 3. Integrated workflow of modern drug design from target discovery to translational optimization. The process begins with disease biology and target discovery, followed by target validation with omics integration, structural bioinformatics and binding-site analysis, virtual screening and hit identification, lead optimization with ADMET profiling, and PK/PD modeling for translational optimization. Supporting computational and pharmacological modules, including genomics, transcriptomics, proteomics, metabolomics, molecular

docking, molecular dynamics, QSAR/machine learning, selectivity, safety, and exposure-response assessment, inform decision-making across the workflow.

Ligand-Based Design, QSAR, and Chemoinformatic Learning

When structural information is limited or when large amounts of activity data already exist, ligand-based design becomes especially valuable. In these settings, the central idea is that molecules sharing relevant chemical features may produce related biological effects, allowing statistical or mechanistic relationships to be inferred from known compounds. Quantitative structure-activity relationship modeling, similarity searching, pharmacophore mapping, and scaffold analysis remain core strategies for lead identification and optimization [14-17,32]. Although sometimes portrayed as older methods in comparison with deep learning, they continue to offer transparency and efficiency when datasets are curated carefully.

QSAR models attempt to relate chemical descriptors to biological readouts such as potency, selectivity, solubility, permeability, or toxicity. Their usefulness depends less on algorithmic sophistication than on assay consistency, descriptor relevance, and applicability domain. A simple interpretable model trained on coherent data may outperform a complex architecture fitted to noisy or heterogeneous measurements. This is one reason why chemoinformatics remains as much about curation as computation [16,32,33]. Outliers, duplicated structures, inconsistent salt forms, assay drift, and missing negative examples can all produce misleading conclusions.

Ligand-based methods are particularly helpful for medicinal chemistry decision-making because they align naturally with iterative optimization. Once an initial series is found, chemists can explore matched molecular pairs, activity cliffs, bioisosteric replacements, and property trends with direct relevance to synthesis planning [14-17]. Filters for drug-likeness, oral exposure, and assay interference also play important roles. The Lipinski and Veber principles remain influential because they summarize broad trends in permeability and absorption, while PAINS alerts remind investigators that some motifs generate misleading assay behavior unrelated to target-specific pharmacology [14,15,17]. None of these rules should be applied dogmatically, but they are useful when interpreted as risk indicators rather than absolute barriers.

The recent rise of machine learning has expanded ligand-based design into a broader predictive framework. Instead of relying only on handcrafted descriptors, models may use graph representations, learned embeddings, multitask training, and generative approaches to propose new structures or prioritize compounds across multiple endpoints [31-35]. Even so, classical medicinal chemistry judgment still matters. The best models do not eliminate the need to consider synthetic accessibility, metabolite risk, stereochemical complexity, or the subtle relationship between potency and developability. In practice, ligand-based design succeeds when computational predictions remain embedded within a disciplined cycle of synthesis, testing, and mechanistic interpretation.

Network Pharmacology and Systems-Level Interpretation

The single-target paradigm has been extraordinarily productive, but it does not fully describe how many effective drugs work in complex diseases. Cancer, neurodegeneration, metabolic syndrome, autoimmune disorders, and infectious diseases often arise from interacting networks rather than isolated lesions. Network pharmacology emerged in response to this

reality by asking how drugs, targets, pathways, and phenotypes are linked across a system and by recognizing that therapeutic benefit may depend on coordinated modulation of multiple nodes [22,23]. This perspective is not an argument against selectivity. Rather, it is an effort to place selectivity within a biological network where pathway redundancy, compensatory signaling, and cell-state transitions may limit the impact of single-node intervention.

Bioinformatic methods make network pharmacology operational. Protein association networks, pathway databases, coexpression analyses, disease modules, and causal inference methods can be combined to map how candidate targets relate to each other and to pathological processes [7,18-24]. In drug design, this is useful for several reasons. First, it helps identify combinations of targets that may produce synergy or reduce resistance. Second, it reveals upstream regulators that might produce broader system effects than downstream markers. Third, it can clarify why compounds with apparently modest potency still produce meaningful phenotypic outcomes if they influence critical network bottlenecks or restore distorted pathway balance.

From a pharmacological standpoint, network analysis sharpens rather than weakens mechanistic reasoning. It encourages investigators to ask whether a proposed target sits at a driver node, whether parallel pathways are likely to bypass the intervention, and whether pathway-level biomarkers can be used to confirm mechanism *in vivo*. It also supports rational polypharmacology, in which multi-target activity is designed deliberately rather than tolerated accidentally [22,23]. This can be especially valuable when disease mechanisms are distributed across interconnected signaling routes.

Nevertheless, network pharmacology has limitations that should not be overlooked. Network edges vary in evidential quality, centrality metrics can be sensitive to missing data, and static network diagrams often underrepresent context, timing, and tissue specificity [24]. A protein may appear central in a database-derived interactome yet be pharmacologically irrelevant in the disease setting of interest. Therefore, systems-level interpretation is most credible when network observations are linked to perturbation data, phenotypic assays, and measurable pharmacodynamic consequences. In the best cases, network pharmacology does not replace molecular mechanism. It provides the wider map within which mechanism can be interpreted realistically.

Multi-Omics Integration in Disease Mechanism and Target Selection

The growing availability of multi-omics data has broadened the evidence base for target discovery and biomarker development. Genomics identifies inherited or somatic variation associated with disease risk or therapeutic response. Transcriptomics reveals altered cell states and pathway activation. Proteomics adds information about abundance, localization, modification, and complex formation. Metabolomics helps connect these upstream changes to biochemical output and physiological consequence [37,38]. When integrated thoughtfully, these layers can reveal mechanistic coherence that is invisible in single-platform analyses.

In drug design, multi-omics is most useful when it reduces ambiguity about causality. A gene that is differentially expressed may not be a good target if protein levels, pathway flux, and phenotypic dependency do not align. Conversely, a modest transcriptional change accompanied by strong protein activation, metabolomic shift, and genetic support can indicate a meaningful intervention point. This convergence principle is increasingly

important in precision medicine, where the goal is not merely to detect differences between patient groups but to identify vulnerabilities that can be modulated therapeutically [37].

Multi-omics integration also supports mechanism-of-action analysis. By comparing omics responses before and after perturbation, investigators can determine whether a compound is producing the intended biological shift, whether adaptive resistance pathways are activated, and whether unexpected liabilities emerge in pathways relevant to toxicity or disease progression [18-20,37,38]. In oncology, for example, dependency maps and CRISPR screens can nominate genes essential in defined contexts, while transcriptomic and phosphoproteomic profiles indicate whether inhibitors truly collapse the corresponding signaling program [36]. Similar logic is being applied in immunology, fibrosis, and neurodegeneration, where cell-state plasticity complicates interpretation.

Yet more data do not automatically produce more insight. Integrating omics layers requires attention to sampling design, batch effects, normalization, missingness, and biological timing. Different omics platforms also capture different timescales of biology, so apparent inconsistencies may reflect temporal separation rather than analytic failure. Pharmacologists therefore play a crucial role in framing the right questions. Which omics change is proximal to mechanism? Which is compensatory? Which is merely a downstream marker? Multi-omics becomes most powerful when interpreted within a causal pharmacological model rather than as an indiscriminate catalog of disease-associated differences[52-55].

ADMET, Developability, and Early Risk Reduction

A recurring lesson in drug discovery is that potency without developability has little practical value. Molecules fail not only because they do not engage their targets, but also because they are insufficiently soluble, poorly permeable, rapidly metabolized, highly protein bound in an unfavorable manner, reactive, transporter-limited, or toxic at concentrations near the desired pharmacological effect [3,13,27]. Early integration of ADMET reasoning therefore remains one of the most effective ways to reduce late-stage attrition.

In silico ADMET models aim to forecast these liabilities before extensive synthesis or in vivo testing. Their endpoints commonly include solubility, permeability, oral absorption, metabolic stability, cytochrome P450 interaction, plasma protein binding, clearance, blood-brain barrier penetration, hERG risk, hepatotoxicity, and mutagenic potential [13,27]. The practical benefit of these models is not perfect prediction but informed triage. They help discovery teams avoid investing heavily in compounds whose physicochemical or liability profiles are clearly incompatible with the intended target product profile.

Pharmacological interpretation is again essential. For example, high plasma protein binding does not inherently preclude efficacy, but it complicates the relationship between nominal exposure and free active concentration [27]. CNS design imposes different constraints than peripheral anti-inflammatory therapy, and an exposure profile appropriate for short-course anti-infective treatment may be unacceptable for a chronic metabolic disease. Rule-based metrics such as Lipinski and Veber criteria remain useful for framing these issues, yet their value lies in signaling probabilistic trends rather than dictating universal thresholds [14,15]. Many successful drugs violate one or more simple rules because route, formulation, target, and therapeutic context matter.

Developability assessment also requires vigilance against false confidence. Predictive models are trained on historical data that may underrepresent newer chemotypes, macrocycles,

covalent ligands, peptides, or targeted degradation modalities. Some liabilities are mechanism dependent and become visible only in relevant cellular or organismal systems. Others arise from metabolites rather than parent compounds. Therefore, early risk reduction works best when computational ADMET, medicinal chemistry intuition, and focused experimentation inform one another. The goal is not to eliminate uncertainty, but to make that uncertainty visible soon enough to guide design choices. In mature discovery programs, this integration often differentiates tractable leads from attractive but ultimately unusable compounds [56-60].

PK/PD Modeling and Translational Pharmacology

The translation of a promising molecule into a viable therapeutic candidate depends on more than potency and selectivity. It requires an understanding of how exposure over time relates to target engagement, downstream biological effect, and clinical outcome. Pharmacokinetic-pharmacodynamic modeling provides the mathematical framework for this interpretation and has become increasingly important in modern design strategies [25,26]. Rather than treating efficacy as a static property of a compound, PK/PD approaches consider how dose, absorption, distribution, metabolism, excretion, and target turnover shape the duration and magnitude of pharmacological action.

Mechanism-based PK/PD models are especially valuable when target biology is nonlinear or delayed relative to exposure. They can describe indirect response systems, feedback loops, biomarker turnover, irreversible inhibition, or target-mediated drug disposition, all of which are common in contemporary therapeutics [25,26]. These models help answer practical design questions. How much free drug is required at the site of action? What peak-to-trough profile is acceptable? Is sustained occupancy necessary, or will transient engagement suffice? Could a compound with weaker in vitro potency still be superior if it displays favorable residence time, tissue retention, or exposure characteristics?

Bioinformatic data enrich this framework by providing biomarkers, pathway readouts, and patient stratification variables that can be incorporated into translational modeling. Gene-expression signatures, protein biomarkers, and disease subtypes can refine dose-response predictions and improve the link between preclinical findings and human expectations [18-20,25]. This is particularly important in precision medicine, where the average response across an unselected population may obscure meaningful benefit in a biologically defined subgroup.

Translational pharmacology also imposes discipline on discovery enthusiasm. A compound that appears compelling in vitro may be unsuitable if the required target coverage cannot be achieved safely, if the pharmacodynamic biomarker is too distal to guide dosing, or if tissue penetration is incompatible with disease location. PK/PD modeling, therefore, is not a late-stage luxury. It is a design tool that should influence target choice, assay setup, and lead optimization from early discovery onward. In well-integrated programs, it converts mechanistic ambition into dosage realism.

Artificial Intelligence in Drug Discovery Workflows

Artificial intelligence and machine learning have moved from speculative promise to practical utility in multiple stages of drug discovery. They are now used for target prioritization, compound generation, property prediction, hit triage, retrosynthetic planning, image-based

phenotypic analysis, and clinical data interpretation [31-35]. Their impact is most visible where large, structured datasets exist and where pattern recognition can complement human judgment. In chemoinformatics, graph neural networks and multitask models have improved the ability to predict biological activity and physicochemical properties across related assay panels. In structural biology, learning-based methods have transformed structure prediction and expanded the set of targets that can be approached rationally [8,9,31-34].

The most useful way to understand AI in drug design is as a decision-support architecture rather than a magical generator of medicines. Models can prioritize compounds that deserve synthesis, highlight nonobvious relationships between assay outcomes, identify repurposing hypotheses from transcriptional or phenotypic data, and propose structures with desired multi-parameter profiles [31-35]. They are particularly effective when discovery teams face combinatorial complexity that exceeds ordinary manual reasoning. Antibiotic discovery work has provided a striking example, showing that learning models can identify structurally distinct active compounds missed by conventional heuristics [35].

Still, performance claims should be interpreted carefully. Machine-learning success depends on data relevance, endpoint definition, negative controls, external validation, and operational context. Models trained on historical medicinal chemistry data may reproduce prior biases rather than discover truly new principles [14,33,34,39]. Generative models may produce molecules that are theoretically attractive but synthetically impractical or biologically implausible. In some cases, the apparent novelty of an output reflects hidden proximity to known chemical space.

Pharmacology remains the critical evaluator of AI outputs. A proposed compound must still be tested for target engagement, functional consequence, selectivity, safety margin, and exposure profile. A predicted target association must still be reconciled with mechanism and disease biology. The strongest discovery environments treat AI as a force multiplier for expert reasoning rather than a replacement for it. This balanced view is likely to endure. As datasets grow richer and models become more multimodal, the importance of careful pharmacological framing will increase rather than diminish.

Challenges, Reproducibility, and Interpretive Pitfalls

Despite major methodological progress, several challenges continue to limit the reliability of pharmacology-informed bioinformatic drug design. One of the most important is data quality. Public databases aggregate information from many laboratories, assay formats, and curation standards. While these resources are invaluable, inconsistencies in endpoint definitions, compound representation, biological annotation, and negative data reporting can distort both mechanistic inference and model training [5-7,24]. Incomplete networks and literature bias may exaggerate the importance of extensively studied proteins while underrepresenting emerging targets.

A second problem is interpretive inflation. Docking scores are often discussed as if they were direct surrogates for binding affinity, and network centrality measures are sometimes treated as proof of causal importance. Machine-learning probabilities may be reported without sufficient attention to calibration, domain shift, or the prevalence of false positives in imbalanced discovery settings [10-13,33,34,39]. These habits encourage premature confidence and can divert resources toward chemically or biologically weak hypotheses.

Good discovery practice therefore requires explicit acknowledgment of what a method can and cannot conclude [61-64].

Reproducibility also remains a concern. Small differences in preprocessing, structure preparation, descriptor calculation, split strategy, or hyperparameter selection can produce meaningfully different outputs. In omics analyses, batch effects and sampling heterogeneity can alter disease signatures substantially. In medicinal chemistry datasets, publication bias toward active compounds can produce unrealistic model performance unless inactive examples are curated with equal care [16,32-34]. These issues are not arguments against computational methods. They are reminders that robust workflows require version control, transparent reporting, external validation, and deliberate confrontation of uncertainty [65-68].

There is also a broader conceptual challenge. Drug discovery rewards action, yet bioinformatic workflows can create an illusion of completeness before genuine biological uncertainty has been resolved. A target may appear validated because it is supported by genetics, network analyses, and docking results, but still fail when tested in a disease-relevant model due to compensation, cell-state plasticity, tissue heterogeneity, or exposure limitations. Conversely, some successful programs begin with noisy or partial evidence but progress because pharmacological experiments reveal an unexpectedly tractable mechanism. The lesson is that discovery should not be organized as a contest between computation and experimentation. It should be structured as an iterative exchange in which each corrects the blind spots of the other [69-72].

From a managerial perspective, decision quality may matter more than data volume. Analyses of the reproducibility crisis in biomedical research have emphasized that more measurements do not necessarily yield better decisions when incentives favor speed over rigor or novelty over robustness [39]. In drug design, this means that disciplined triage, conservative interpretation, and mechanistic follow-up remain indispensable even in highly automated environments.

Future Directions

Several trends are likely to shape the next phase of pharmacology and bioinformatic integration in drug design. First, multimodal modeling will become more common. Rather than analyzing chemical, structural, omic, and phenotypic data in separate silos, future systems will increasingly integrate them into unified representations of target behavior and compound effect [31-35,37]. This should improve prioritization by allowing discovery teams to compare candidates not only by predicted affinity or potency, but by the coherence of their entire mechanistic profile.

Second, target space will continue to expand. Structural prediction, cryo-electron microscopy, covalent chemistry, and targeted protein degradation are opening opportunities against proteins and complexes once regarded as intractable [8,9]. As this happens, bioinformatics will play a growing role in identifying the contexts in which such targets matter most, while pharmacology will determine whether the mode of intervention produces meaningful and controllable biology.

Third, the boundary between biomarker science and drug design will narrow. Omics-derived biomarkers, pathway signatures, and functional readouts are increasingly being developed in parallel with candidate molecules rather than after the fact [18-20,25,37,38]. This co-

development model should improve translational efficiency because mechanism confirmation, patient selection, and dose optimization can be planned earlier.

Finally, the field is likely to move toward more explicit uncertainty management. Instead of presenting models as deterministic engines, mature workflows will score evidence quality, define applicability domains, and incorporate negative results more systematically. This cultural shift may be as important as any algorithmic innovation. Drug discovery benefits not from the appearance of certainty, but from the ability to make better decisions under uncertainty. Pharmacology and bioinformatics are uniquely suited to this task when used together: one grounds therapeutic ambition in mechanism, and the other provides the integrative perspective needed to navigate biological complexity [73-76].

Conclusion

Modern drug design is increasingly defined by the productive tension between computational scale and pharmacological interpretation. Bioinformatic analysis can reveal disease signatures, prioritize targets, integrate networks, exploit structural information, and guide the exploration of vast chemical spaces. Pharmacology determines whether those insights correspond to meaningful intervention points, feasible exposure profiles, and therapeutically useful mechanisms. Neither discipline is sufficient alone. Bioinformatics without pharmacology risks elegant but biologically shallow predictions, while pharmacology without computational integration risks missing the broader patterns that now define target biology and therapeutic opportunity.

The most successful discovery strategies are therefore integrative by design. They combine database curation, omics analysis, structural reasoning, virtual screening, medicinal chemistry, ADMET forecasting, and PK/PD thinking within a single iterative workflow. As machine learning and multimodal modeling continue to mature, their value will depend not on replacing expert judgment but on sharpening it. The future of drug design will belong to programs that use computational tools to ask better questions and pharmacological science to answer them convincingly.

References

1. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat Rev Drug Discov.* 2010;9(3):203-214.
2. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. *Br J Pharmacol.* 2011;162(6):1239-1249.
3. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. *Nat Rev Drug Discov.* 2015;14(7):475-486.
4. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, et al. Impact of high-throughput screening in biomedical research. *Nat Rev Drug Discov.* 2011;10(3):188-195.
5. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res.* 2018;46(D1):D1074-D1082.
6. Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, et al. The ChEMBL database in 2017. *Nucleic Acids Res.* 2017;45(D1):D945-D954.

7. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 2019;47(D1):D607-D613.
8. Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Res.* 2022;50(D1):D439-D444.
9. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. *Nature.* 2021;596(7873):583-589.
10. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. *Nat Rev Drug Discov.* 2004;3(11):935-949.
11. Lionta E, Spyrou G, K Vassilatis D, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. *Curr Top Med Chem.* 2014;14(16):1923-1938.
12. Hollingsworth SA, Dror RO. Molecular dynamics simulation for all. *Neuron.* 2018;99(6):1129-1143.
13. Van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? *Nat Rev Drug Discov.* 2003;2(3):192-204.
14. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev.* 2001;46(1-3):3-26.
15. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. *J Med Chem.* 2002;45(12):2615-2623.
16. Walters WP, Murcko MA. Prediction of 'drug-likeness'. *Adv Drug Deliv Rev.* 2002;54(3):255-271.
17. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J Med Chem.* 2010;53(7):2719-2740.
18. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.* 2005;102(43):15545-15550.
19. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science.* 2006;313(5795):1929-1935.
20. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Syst.* 2015;1(6):417-425.
21. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* 2003;13(11):2498-2504.
22. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol.* 2008;4(11):682-690.
23. Csermely P, Korcsmaros T, Kiss HJM, London G, Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. *Pharmacol Ther.* 2013;138(3):333-408.
24. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. Data completeness—the Achilles heel of drug-target networks. *Nat Biotechnol.* 2008;26(9):983-984.

25. Danhof M, de Jongh J, De Lange ECM, Della Pasqua O, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling in translational drug research. *Trends Pharmacol Sci.* 2007;28(3):122-129.
26. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. *J Pharmacokinet Pharmacodyn.* 2001;28(6):507-532.
27. Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. *Nat Rev Drug Discov.* 2010;9(12):929-939.
28. Ferreira LG, dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. *Molecules.* 2015;20(7):13384-13421.
29. Gorgulla C, Boeszoermyeni A, Wang ZF, Fischer PD, Coote PW, Das KM, et al. An open-source drug discovery platform enables ultra-large virtual screens. *Nature.* 2020;580(7805):663-668.
30. Maia EHB, Assis LC, de Oliveira TA, da Silva AM Jr, Taranto AG. Structure-based virtual screening: from classical to artificial intelligence. *Front Chem.* 2020;8:343.
31. Schneider G. Automating drug discovery. *Nat Rev Drug Discov.* 2018;17(2):97-113.
32. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. *Drug Discov Today.* 2018;23(6):1241-1250.
33. Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, et al. Exploiting machine learning for end-to-end drug discovery and development. *Nat Mater.* 2019;18(5):435-441.
34. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov.* 2019;18(6):463-477.
35. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. *Cell.* 2020;180(4):688-702.e13.
36. Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a Cancer Dependency Map. *Cell.* 2017;170(3):564-576.e16.
37. Hasin Y, Seldin M, Lusi A. Multi-omics approaches to disease. *Genome Biol.* 2017;18(1):83.
38. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. *Nat Rev Mol Cell Biol.* 2016;17(7):451-459.
39. Scannell JW, Bosley J. When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis. *PLoS One.* 2016;11(2):e0147215.
40. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. *Science.* 2014;346(6213):1258096.
41. Chikava M, Tsintsadze T, Mishelashvili K, Sulashvili N. Modern theories of homeopathic Nanopharmacology. *Nano Studies.* 2014 Sep;(3):107-110.
42. Arabuli L, Sulashvili N, Kvizhinadze N. Synthesis and in vitro Cytotoxicity Testing of New Cyclen-Peptide Conjugations. *Caucasus Journal of Health Sciences and Public Health.* 2016 Jun;1(Suppl 1):105-109.
43. Arabuli L, Jezek R, Macek T, Lovecka P, Nikoleishvili E, Sulashvili N, et al. Solid-Phase Synthesis and In Vitro Cytotoxicity of New Peptide Functionalized Cyclencarboxymethylen and L-DOPA Hybrids. *Medicinal Chemistry (Los Angeles).* 2017;7(12):398-407.
44. Arabuli L, Sulashvili N, Kvizhinadze N. New Derivatives of 10-chloro-5,10-dihydrophenarsazine with Potential Biological Activity. *Caucasus Journal of Health Sciences and Public Health.* 2017 Jun;1(Suppl 2):113.

45. Gakhutishvili M, Brostow W, Sulashvili N, Pirtskhalava T. Antibacterial Arsenic Doped Polymer Composites in Healthcare and Hospitals. In: Abstracts of Seventh (7th) International Caucasian Symposium on Polymers and Advanced Materials. Tbilisi; 2021 Jul 27-30. p. 32.
46. Avagimyan A, Kajaia A, Gabunia L, Ghambashidze K, Sulashvili N, Ratiani L, et al. Urotensin-II As a Promising Key-Point of Cardiovascular Disturbances Sequel. Current Problems in Cardiology. 2021 Nov 27;101074.
47. Sulashvili N, Gorgaslidze N, Beglaryan M. The Scientific Achievements of the Problems and Perspectives of Coronavirus Vaccine Enhancement for Prevention and Prophylaxis of the COVID-19 Diseases. In: Materials of the VII International Scientific-Practical Conference "Social Pharmacy: State, Problems and Prospects". Kharkiv: National Pharmaceutical University of Ukraine; 2021 Sep 23-24. p. 117-149.
48. Sulashvili N, Beglaryan M, Gorgaslidze N. The Scientific Discussion of the Pharmacists' State Problems and Perspectives of Regular Judging by the Position of Patients in Georgia. In: Materials of the VII International Scientific-Practical Conference "Social Pharmacy: State, Problems and Prospects". Kharkiv: National Pharmaceutical University of Ukraine; 2021 Sep 23-24. p. 81-106.
49. Sulashvili N, Gorgaslidze N, Beglaryan M. The Scientific Debates of Peculiarities of Problems, Perspectives and Role of the Clinical Pharmacists Worldwide in General in the XXI Century. In: Materials of the VII International Scientific-Practical Conference "Social Pharmacy: State, Problems and Prospects". Kharkiv: National Pharmaceutical University of Ukraine; 2021 Sep 23-24. p. 284-317.
50. Sulashvili N, Gorgaslidze N, Beglaryan M. The Features of Problems and Prospects Clinical Pharmacist in General and Aspects of Pharmaceutical Care in Different Directions of Action of Pharmaceutics and Public Health. In: Materials of VII International Scientific and Practical conferences "Technological and Biopharmaceutical Aspects of Drugs Developing with Different Orientation of Action". Kharkiv: National Pharmaceutical University of Ukraine; 2022 Nov 24-25. p. 119-145.
51. Sulashvili N, Gorgaslidze N, Beglaryan M, Chichoyan N, Gabunia L, Zarnadze I, et al. Scientific Talks of the Features of the Pharmacist' Profession, Essential Role, Achievements, Problems, Aspects and Higher Pharmaceutical Educational Advancement Issue Perspectives in the Context of Patients Safety Locally and Globally in XXI Century. Bulletin of the Medical Institute After Mehrabyan. 2021;11:37-68.
52. Sulashvili N, Alavidze N, Kvizhinadze N, Okropiridze T. The Features of Pharmacists' Professional Issue Approaches, Ensuring, Aspirations and Requirements According the Mind of Patients in Georgia. In: Materials of the international scientific and practical conference "Current Issues of Pharmacology, Clinical Pharmacology and Clinical Pharmacy". Kharkiv: National Pharmaceutical University of Ukraine; 2022 Oct 27-28. p. 20-36.
53. Sulashvili N, Beglaryan M, Gorgaslidze N. The Scientific Discussion of Inclination, Achievements, Tenacities, Innovations, Aspiration and Perspectives of Pharmacists' Profession in Georgia and Globally. Bulletin of the Medical College After Mehrabyan. 2022;13:31-54.
54. Sulashvili N, Beglaryan M, Gorgaslidze N. Scientific Talks of the Features of the Pharmacist' Profession, Essential Role, Achievements, Problems, Aspects and Higher Pharmaceutical Educational Advancement Issue Perspectives in the Context of Patients Safety Locally and Globally in XXI Century. In: Proceedings of the III International Scientific and Practical Conference

- "Modern Pharmacy -- Science and Practice". Kutaisi: Akaki Tsereteli State University; 2023 Sep 5-30. p. 183-204.
55. Sulashvili N, Beglaryan M, Gorgaslidze N. The Scientific Talks of the Manifestation of Pharmacists New Engagement, Purpose, Involvement, Challenges, Professional Development, Perspectives and Modern Trends Implementation in Pharmacy Education, According New Impediments in XXI Century in the Domestic and International Context in General. In: Materials of the III International Scientific and Practical Conference, Dedicated to the 40th Anniversary of the Foundation of the Department of Organization, Economics and Management of Pharmacy. Kharkiv: National Pharmacy University of Ukraine; 2024 Oct 23-24. p. 370-388.
 56. Arabuli L, Nikoleishvili E, Sulashvili N. Solid-Phase Synthesis of Bifunctional Macrocyclic Polyamines Targeting Neurodegenerative diseases. In: International scientific conference "Future Technologies and Quality of Life". Batumi: TSMU; 2017 Sep 29-Oct 1. p. 3.
 57. Arabuli L, Sulashvili N, Kvizhinadze N. New Derivatives of 10-chloro-5,10-dihydrophenarsazine with Potential Biological Activity. In: International Science and Innovation Festival 2017. Tbilisi: TSMU; 2017 Sep. p. 12-13.
 58. Sulashvili N, Gorgaslidze N, Beglaryan M. The Scientific Discussion of Features, Challenges, Perspectives of Pharmacists' and Professional Issue Aspects in Different Directions of Action in Pharmacy, Medicine and Public Health in Georgia. In: Materials of VII International Scientific and Practical conferences "Technological and Biopharmaceutical Aspects of Drugs Developing with Different Orientation of Action". Kharkiv: National Pharmaceutical University of Ukraine; 2022 Nov 24-25. p. 231-260.
 59. Sulashvili N, Gorgaslidze N, Beglaryan M, Lobjanidze T, Chichoyan N, Gabunia L, et al. The Manifestation of the Key Issue Aspects of Pharmacists' Professional Aspiration, Development, Perfection and Social Pharmacy State Problems, Prospects, Pharmaceutical Education and Management Features in General. In: Proceedings of the III International Scientific and Practical Conference "Fundamental and Applied Research in the Field of Pharmaceutical Technology". Kharkiv: National Pharmaceutical University of Ukraine; 2023 Nov 24. p. 166-199.
 60. Sulashvili N, Beglaryan M, Gorgaslidze N. The Key Issue of Manifestation of Modern Aspects of Achievements of Pharmacists Profession, Pharmaceutical Education, Science and Organizational Aspects of Pharmaceutics in Georgia. In: Materials of II Scientific and Practical International Conference On The Topic "Modern Aspects of Achievements Fundamental and Applied Medical and Biological Areas Medical and Pharmaceutical Education and Science". Kharkiv: Kharkiv National Medical University; 2023 Nov 17. p. 271-288.
 61. Rekhviashvili D, Chakhunashvili G, Megrelishvili N, Taboridze I. Diabetic Dyslipidemia in Georgian Children with Type 1 Diabetes. Translational and Clinical Medicine-Georgian Medical Journal. 2026 Jun 30;11(2):41
 62. Rekhviashvili D, Chakhunashvili G, Chkhaidze M, Abdushelishvili N, Arveladze G, Kevlishvili S, Taboridze I. ASSESSMENT OF THE LIPID SPECTRUM IN GEORGIAN CHILDREN WITH TYPE 1 DIABETES MELLITUS. Georgian Medical News. 2026 Apr 1(373):30-5.
 63. Shervashidze T, Kvanchakhadze R, Shervashidze M, Abuladze D, Jashi L, Taboridze I. Metabolic and Cardiometabolic Changes After Sleeve Gastrectomy in a Patient With Type 1 Diabetes and Morbid Obesity: A CARE-Compliant Case Report. The Georgian Medical Journal. 2026 Mar 20;1(1):185-98.

64. Dundua K, Taboridze I, Kvanchakhadze R, Abesadze I, Jashi L. CORRELATIONS BETWEEN HOMOCYSTEINE AND VITAMIN B12 IN TYPE 2 DIABETES TREATED WITH METFORMIN. Georgian medical news. 2026 Mar(372):6-12.
65. Gujejiani L, Latsuzbaia K, Taboridze I. Prinzmetal Angina: A Case of Recurrent Ventricular Fibrillation. Eur Sci J. 2026;22(12).
66. Kokhreidze A, Saginadze L, Kvanchaxadze R, Gordeladze M, Janjgava S, Taboridze I. THE HIDDEN LINK: HOW VITAMIN D AND ZINC INFLUENCE GROWTH AND MENTAL HEALTH IN CHILDREN. Georgian Medical News. 2025 Mar 1(360):13-9.
67. Dundua K, Taboridze I, Kvanchakhadze R. Evaluation of Vitamin B12 and Homocysteine Status in Patients with Type 2 Diabetes Mellitus without Metformin Therapy. Scientific Journal „Spectri “. 2025;12(2).
68. Shervashidze T, Kvanchakhadze R, Abuladze D, Jashi L, Shervashidze M, Sakvarelidze I, Makharadze M, Taboridze I. THE IMPACT OF BARIATRIC SURGERY ON TYPE 2 DIABETES MELLITUS REMISSION IN THE GEORGIAN POPULATION. Georgian Medical News. 2025 Jan 1(358):106-12.
69. Arabidze K, Gogokhia I, Sokhadze K, Kintsurashvili N, Tsiklauri M, Gogichaishvili T, Taboridze I. THE EVALUATION OF THE RISK OF COMPLICATIONS DURING MULTIMODAL AND OPIOID ANESTHESIA IN BARIATRIC SURGERY AND ABDOMINOPLASTY. Georgian Medical News. 2023 Dec 1(345):67-71.
70. Kacharava T, Giorgadze E, Janjgava S, Lomtadze N, Taboridze I. Correlation between vitamin B12 deficiency and autoimmune thyroid diseases. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2023 Jan 1;23(1):86-94.
71. Lomtadze N, Giorgadze E, Janjgava S, Kacharava T, Taboridze I. The relationship between insulin resistance and thyroid volume in Georgia. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2023 Sep 1;23(10):1318-25.
72. Chigogidze M, Pagava Z, Taboridze I, Lomia N, Saatashvili G, Sharashidze N. ASSESSMENT OF CORONARY COLLATERAL CIRCULATION PREDICTORS AMONG PATIENTS WITH ACUTE CORONARY SYNDROME IN POPULATION GEORGIA. Georgian Medical News. 2023 Jan 1(334):57-64.
73. Gogishvili G, Petriashvili S, Nanobashvili N, Megrelishvili N, Taboridze I. Evaluation of Diagnostic Value of Non-HDL Lipoproteins in Georgian Population Under 45 Years of Age with Coronary Heart Disease. Sci J Spectri. 2021;5:15-19.
74. Arabidze K, Gogokhia I, Lebanidze N, Taboridze I. POSTOPERATIVE PAIN AND MULTIMODAL ANESTHESIA IN ABDOMINAL PLASTIC AND BARIATRIC SURGERY. Int J Innov Med Healthc. 2023;4(1):23-28.
75. Diasamidze E, Gvenetadze T, Antadze G, Taboridze I, Giorgobiani G. THE IMPACT OF ANEMIA ON THE DEVELOPMENT OF INCISIONAL HERNIA, PROSPECTIVE STUDY. Georgian Medical News. 2025 Dec 1(369):63-7.
76. Kokhreidze A, Saginadze L, Kvanchaxadze R, Gordeladze M, Janjgava S, Taboridze I, et al. MICRONUTRIENTS AND THE MIND: HOW ZINC AND VITAMIN D AFFECT CHILD DEVELOPMENT. Proc Int Res Educ Train Cent. 2025;35(2).